Expanded access to Ossium HPC (deceased-donor bone marrow) for transplant
Official title: A Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for HOPE Patients With Hematologic Malignancies or Disorders
Run by Ossium Health, Inc. · NCT07145411 · Data updated 2026-11-12
This program provides Ossium's deceased-donor bone marrow (HPC, Marrow) to people aged 12–80 who need an allogeneic bone marrow transplant but cannot join the PRESERVE protocol.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 12 Years to 80 Years |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Ossium Health, Inc. Industry-sponsored |
| Locations | 5 sites (Birmingham, Alabama and 4 other locations) |
| Status | Recruiting |
| Started | June 27, 2024 |
| Main results expected | August 2027 |
| Study ends | August 2029 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT07145411 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged 12–80 who are eligible for allogeneic bone marrow transplant for conditions such as ALL, AML, lymphomas, CLL, or CML and whose treating physician determines that potential benefit outweighs risk.
✕Probably not a fit
Patients younger than 12 or older than 80, those who are not candidates for allogeneic transplant, have contraindications to transplantation, or who can already access the PRESERVE protocol are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This expanded-access program offers Ossium's HPC, Marrow—bone marrow recovered from deceased organ and tissue donors—to patients who are candidates for allogeneic transplant but cannot enroll in the PRESERVE protocol. Participating transplant centers will identify eligible patients (ages 12–80) whose treating physician judges that the potential benefit outweighs the risks, arrange product procurement, and proceed with transplantation according to local standard practice. The program is observational and focuses on providing access rather than testing a new therapeutic procedure, with outcomes and safety data collected as part of follow-up. Sites include University of Alabama at Birmingham, Henry Ford Health (Detroit), and The Ohio State University Medical Center (Columbus).
Why it matters
Potential benefit: If successful, this program could increase access to compatible marrow grafts and enable more patients to receive potentially curative allogeneic transplants.
How similar studies have gone: Allogeneic bone marrow transplantation is an established treatment, but recovering marrow from deceased donors is a relatively new approach with limited long-term outcome data and is being explored in programs like PRESERVE.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients aged 12-80 may be eligible\* to receive bone marrow for transplantation through the Ossium HOPE Program if: Their treating physician determined they are eligible for allogeneic bone marrow transplant Their treating physician determined that the potential benefit outweighs the potential risks
Where it's running
-
University of Alabama, Birmingham
Birmingham, Alabama, United States Recruiting -
City of Hope
Duarte, California, United States Recruiting -
Henry Ford Health
Detroit, Michigan, United States Recruiting -
The Ohio State University Medical Center
Columbus, Ohio, United States Recruiting -
Tristar Centennial Medical Center
Nashville, Tennessee, United States Recruiting
Study contacts
- Study coordinator: Preethi Prasad, Senior Director Clinical Operations
- Email: preethi.prasad@ossiumhealth.com
- Phone: 415-513-5535
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.